Literature DB >> 23637397

Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Celia Perales1, Nathan M Beach, Isabel Gallego, Maria Eugenia Soria, Josep Quer, Juan Ignacio Esteban, Charles Rice, Esteban Domingo, Julie Sheldon.   

Abstract

Cell culture-produced hepatitis C virus (HCV) has been subjected to up to 100 serial passages in human hepatoma cells in the absence or presence of different doses of alpha interferon (IFN-α). Virus survival, genetic changes, fitness levels, and phenotypic traits have been examined. While high initial IFN-α doses (increasing from 1 to 4 IU/ml) did not allow HCV survival beyond passage 40, a gradual exposure (from 0.25 to 10 IU/ml) allowed the virus to survive for at least 100 passages. The virus passaged in the presence of IFN-α acquired IFN-α resistance as evidenced by enhanced progeny production and viral protein expression in an IFN-α environment. A partial IFN-α resistance was also noted in populations passaged in the absence of IFN-α. All lineages acquired adaptative mutations, and multiple, nonsynonymous mutations scattered throughout the genome were present in IFN-α-selected populations. Comparison of consensus sequences indicates a dominance of synonymous versus nonsynonymous substitutions. IFN-α-resistant populations displayed decreased sensitivity to a combination of IFN-α and ribavirin. A phenotypic trait common to all assayed viral populations is the ability to increase shutoff host cell protein synthesis, accentuated in infections with IFN-α-selected populations carried out in the presence of IFN-α. The trait was associated with enhanced phosphorylation of protein kinase R (PKR) and eIF2α, although other contributing factors are likely. The results suggest that multiple, independent mutational pathways can confer IFN-α resistance to HCV and might explain why no unified picture has been obtained regarding IFN-α resistance in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637397      PMCID: PMC3700284          DOI: 10.1128/JVI.02824-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  126 in total

1.  Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.

Authors:  M Kurosaki; N Enomoto; T Murakami; I Sakuma; Y Asahina; C Yamamoto; T Ikeda; S Tozuka; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

2.  Modulation of the type I interferon pathways by culture-adaptive hepatitis C virus core mutants.

Authors:  Ju-Il Kang; Young-Chan Kwon; Byung-Yoon Ahn
Journal:  FEBS Lett       Date:  2012-04-09       Impact factor: 4.124

Review 3.  Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy.

Authors:  C M Lange; C Sarrazin; S Zeuzem
Journal:  Aliment Pharmacol Ther       Date:  2010-03-31       Impact factor: 8.171

4.  Cell culture and infection system for hepatitis C virus.

Authors:  Takanobu Kato; Tomoko Date; Asako Murayama; Kenichi Morikawa; Daisuke Akazawa; Takaji Wakita
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.

Authors:  R Jardi; F Rodriguez-Frias; M Schaper; G Ruiz; I Elefsiniotis; R Esteban; M Buti
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

7.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.

Authors:  F Puig-Basagoiti; J C Sáiz; X Forns; S Ampurdanès; M Giménez-Barcons; S Franco; A Sánchez-Fueyo; J Costa; J M Sánchez-Tapias; J Rodés
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

10.  Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.

Authors:  Makoto Kadokura; Shinya Maekawa; Ryota Sueki; Mika Miura; Kazuki Komase; Hiroko Shindo; Fumitake Amemiya; Tomoyoshi Uetake; Taisuke Inoue; Minoru Sakamoto; Mina Nakagawa; Naoya Sakamoto; Mamoru Watanabe; Nobuyuki Enomoto
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

View more
  37 in total

1.  Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.

Authors:  B Dominguez-Molina; K Machmach; C Perales; L Tarancon-Diez; I Gallego; J L Sheldon; M Leal; E Domingo; E Ruiz-Mateos
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

2.  Broad and Dynamic Diversification of Infectious Hepatitis C Virus in a Cell Culture Environment.

Authors:  Isabel Gallego; María Eugenia Soria; Carlos García-Crespo; Qian Chen; Patricia Martínez-Barragán; Soumaya Khalfaoui; Brenda Martínez-González; Irene Sanchez-Martin; Inés Palacios-Blanco; Ana Isabel de Ávila; Damir García-Cehic; Juan Ignacio Esteban; Jordi Gómez; Carlos Briones; Josep Gregori; Josep Quer; Celia Perales; Esteban Domingo
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

3.  Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.

Authors:  Julie Sheldon; Nathan M Beach; Elena Moreno; Isabel Gallego; David Piñeiro; Encarnación Martínez-Salas; Josep Gregori; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Esteban Domingo; Celia Perales
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 4.  Viral quasispecies.

Authors:  Raul Andino; Esteban Domingo
Journal:  Virology       Date:  2015-03-29       Impact factor: 3.616

5.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

6.  Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment.

Authors:  Elena Moreno; Isabel Gallego; Josep Gregori; Adriana Lucía-Sanz; María Eugenia Soria; Victoria Castro; Nathan M Beach; Susanna Manrubia; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Jordi Gómez; Pablo Gastaminza; Esteban Domingo; Celia Perales
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

7.  Synergistic lethal mutagenesis of hepatitis C virus.

Authors:  Isabel Gallego; María Eugenia Soria; Josep Gregori; Ana I de Ávila; Carlos García-Crespo; Elena Moreno; Ignacio Gadea; Jaime Esteban; Ricardo Fernández-Roblas; Juan Ignacio Esteban; Jordi Gómez; Josep Quer; Esteban Domingo; Celia Perales
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

8.  Genome-Wide Mutagenesis of Hepatitis C Virus Reveals Ability of Genome To Overcome Detrimental Mutations.

Authors:  Deepak Singh; Shalini Soni; Shaheen Khan; Aditya N Sarangi; Ragothaman M Yennamalli; Rakesh Aggarwal; Naga Suresh Veerapu
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

9.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 10.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.